338 related articles for article (PubMed ID: 33116117)
1. Metformin as a senostatic drug enhances the anticancer efficacy of CDK4/6 inhibitor in head and neck squamous cell carcinoma.
Hu Q; Peng J; Jiang L; Li W; Su Q; Zhang J; Li H; Song M; Cheng B; Xia J; Wu T
Cell Death Dis; 2020 Oct; 11(10):925. PubMed ID: 33116117
[TBL] [Abstract][Full Text] [Related]
2. The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma.
Ku BM; Yi SY; Koh J; Bae YH; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Oncotarget; 2016 Mar; 7(12):14803-13. PubMed ID: 26909611
[TBL] [Abstract][Full Text] [Related]
3. SPH3643: A novel cyclin-dependent kinase 4/6 inhibitor with good anticancer efficacy and strong blood-brain barrier permeability.
Liao X; Hong Y; Mao Y; Chen N; Wang Q; Wang Z; Zhang L; Wang L; Shi C; Shi W; Ge H; Li A; Li X; Xia G; Liu Y
Cancer Sci; 2020 May; 111(5):1761-1773. PubMed ID: 32103527
[TBL] [Abstract][Full Text] [Related]
4. Metformin Inhibits Progression of Head and Neck Squamous Cell Carcinoma by Acting Directly on Carcinoma-Initiating Cells.
Wu X; Yeerna H; Goto Y; Ando T; Wu VH; Zhang X; Wang Z; Amornphimoltham P; Murphy AN; Tamayo P; Chen Q; Lippman SM; Gutkind JS
Cancer Res; 2019 Sep; 79(17):4360-4370. PubMed ID: 31292160
[TBL] [Abstract][Full Text] [Related]
5. SKLB188 inhibits the growth of head and neck squamous cell carcinoma by suppressing EGFR signalling.
Barzegar M; Ma S; Zhang C; Chen X; Gu Y; Shang C; Jiang X; Yang J; Nathan CA; Yang S; Huang S
Br J Cancer; 2017 Oct; 117(8):1154-1163. PubMed ID: 28873083
[TBL] [Abstract][Full Text] [Related]
6. Metformin suppresses growth of human head and neck squamous cell carcinoma via global inhibition of protein translation.
Sikka A; Kaur M; Agarwal C; Deep G; Agarwal R
Cell Cycle; 2012 Apr; 11(7):1374-82. PubMed ID: 22421144
[TBL] [Abstract][Full Text] [Related]
7. The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation.
Yadav V; Burke TF; Huber L; Van Horn RD; Zhang Y; Buchanan SG; Chan EM; Starling JJ; Beckmann RP; Peng SB
Mol Cancer Ther; 2014 Oct; 13(10):2253-63. PubMed ID: 25122067
[TBL] [Abstract][Full Text] [Related]
8. CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest.
Wang J; Li Q; Yuan J; Wang J; Chen Z; Liu Z; Li Z; Lai Y; Gao J; Shen L
J Transl Med; 2017 Jun; 15(1):127. PubMed ID: 28578693
[TBL] [Abstract][Full Text] [Related]
9. Semi-mechanistic pharmacokinetic/pharmacodynamic modeling of the antitumor activity of LY2835219, a new cyclin-dependent kinase 4/6 inhibitor, in mice bearing human tumor xenografts.
Tate SC; Cai S; Ajamie RT; Burke T; Beckmann RP; Chan EM; De Dios A; Wishart GN; Gelbert LM; Cronier DM
Clin Cancer Res; 2014 Jul; 20(14):3763-74. PubMed ID: 24850847
[TBL] [Abstract][Full Text] [Related]
10. Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal squamous cell carcinoma.
Qie S; Yoshida A; Parnham S; Oleinik N; Beeson GC; Beeson CC; Ogretmen B; Bass AJ; Wong KK; Rustgi AK; Diehl JA
Nat Commun; 2019 Mar; 10(1):1296. PubMed ID: 30899002
[TBL] [Abstract][Full Text] [Related]
11. CDK4/6 and autophagy inhibitors synergize to suppress the growth of human head and neck squamous cell carcinomas.
Duah E; Seligson ND; Persaud AK; Dam Q; Pabla N; Rocco JW; Li J; Poi M
Mol Carcinog; 2023 Aug; 62(8):1201-1212. PubMed ID: 37132760
[TBL] [Abstract][Full Text] [Related]
12. Patient-Derived Xenografts for Prognostication and Personalized Treatment for Head and Neck Squamous Cell Carcinoma.
Karamboulas C; Bruce JP; Hope AJ; Meens J; Huang SH; Erdmann N; Hyatt E; Pereira K; Goldstein DP; Weinreb I; Su J; O'Sullivan B; Tiedemann R; Liu FF; Pugh TJ; Bratman SV; Xu W; Ailles L
Cell Rep; 2018 Oct; 25(5):1318-1331.e4. PubMed ID: 30380421
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models.
Lee MS; Helms TL; Feng N; Gay J; Chang QE; Tian F; Wu JY; Toniatti C; Heffernan TP; Powis G; Kwong LN; Kopetz S
Oncotarget; 2016 Jun; 7(26):39595-39608. PubMed ID: 27167191
[TBL] [Abstract][Full Text] [Related]
14. Dual blockade of EGFR and CDK4/6 delays head and neck squamous cell carcinoma progression by inducing metabolic rewiring.
Chaudhary S; Pothuraju R; Rachagani S; Siddiqui JA; Atri P; Mallya K; Nasser MW; Sayed Z; Lyden ER; Smith L; Gupta SD; Ralhan R; Lakshmanan I; Jones DT; Ganti AK; Macha MA; Batra SK
Cancer Lett; 2021 Jul; 510():79-92. PubMed ID: 33878394
[TBL] [Abstract][Full Text] [Related]
15. Metformin enhances gefitinib efficacy by interfering with interactions between tumor-associated macrophages and head and neck squamous cell carcinoma cells.
Yin X; Han S; Song C; Zou H; Wei Z; Xu W; Ran J; Tang C; Wang Y; Cai Y; Hu Q; Han W
Cell Oncol (Dordr); 2019 Aug; 42(4):459-475. PubMed ID: 31001733
[TBL] [Abstract][Full Text] [Related]
16. Targeting the CDK4/6-Rb Pathway Enhances Response to PI3K Inhibition in
Shi R; Li M; Raghavan V; Tam S; Cabanero M; Pham NA; Shepherd FA; Moghal N; Tsao MS
Clin Cancer Res; 2018 Dec; 24(23):5990-6000. PubMed ID: 30093452
[TBL] [Abstract][Full Text] [Related]
17. Stromal Senescence By Prolonged CDK4/6 Inhibition Potentiates Tumor Growth.
Guan X; LaPak KM; Hennessey RC; Yu CY; Shakya R; Zhang J; Burd CE
Mol Cancer Res; 2017 Mar; 15(3):237-249. PubMed ID: 28039358
[TBL] [Abstract][Full Text] [Related]
18. Metformin increases natural killer cell functions in head and neck squamous cell carcinoma through CXCL1 inhibition.
Crist M; Yaniv B; Palackdharry S; Lehn MA; Medvedovic M; Stone T; Gulati S; Karivedu V; Borchers M; Fuhrman B; Crago A; Curry J; Martinez-Outschoorn U; Takiar V; Wise-Draper TM
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36328378
[TBL] [Abstract][Full Text] [Related]
19. Potential role of cyclin-dependent kinase 4/6 inhibitors in the treatment of squamous cell carcinoma of the head and neck.
van Caloen G; Machiels JP
Curr Opin Oncol; 2019 May; 31(3):122-130. PubMed ID: 30986809
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of UCN-01 in carcinomas of the head and neck is associated with altered expression of cyclin D3 and p27(KIP1).
Patel V; Lahusen T; Leethanakul C; Igishi T; Kremer M; Quintanilla-Martinez L; Ensley JF; Sausville EA; Gutkind JS; Senderowicz AM
Clin Cancer Res; 2002 Nov; 8(11):3549-60. PubMed ID: 12429646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
